Brief: Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400
15/07/2024 21:12
July 15 (Reuters) - Eton Pharmaceuticals Inc ETON.O :
* ETON PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG
APPLICATION FOR ET-400 (HYDROCORTISONE ORAL SOLUTION)
* ETON PHARMACEUTICALS INC: PRESCRIPTION DRUG USER FEE ACT
(PDUFA)
TARGET ACTION DATE IS FEBRUARY 28, 2025
* ETON PHARMACEUTICALS INC - ET-400 PATENT PROTECTION
THROUGH 2043
Source text for Eikon: ID:nGNX4X3nVX
Further company coverage: ETON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eton Pharmaceuticals
See all newsBrief: Eton Pharmaceuticals Under Agreement, Co Pays Aquestive Upfront License Fee Of $10 Million - SEC Filing
Aquestive rises on US licensing deal for seizure drug with Eton Pharma
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
U.S. STOCKS ON THE MOVE-Fox, Sun Communities, Reddit, drone firms
U.S. STOCKS ON THE MOVE-Boost Run, Nektar Therapeutics, Swarmer